Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per year, Susvimo ...

Diabetic retinopathy is an eye disease that can develop in people with diabetes. Without treatment, it can lead to vision loss and blindness. Fundus photography forms part of fundoscopy ...

Diabetic vitreous hemorrhage is linked to neuropathologic changes in specific brain regions, as identified by voxel-based ...

The FDA approved Susvimo for the treatment of diabetic macular edema ... transportation difficulties and other factors contributed to diabetic retinopathy screening nonattendance among patients ...

EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.